Article No
AFC-H955NR-0.1
Anti-HLA-G Purified Azide Free
Anti-HLA-G Purified Azide Free
Antibodies Primary
Specifications
| Application | FC, IP, IHC, ICC, ELISA |
| Article No | AFC-H955NR-0.1 |
| Biosite Brand | Biosite Flow |
| Country Availability | all |
| Clone | MEM-G/9 |
| Clone Type | monoclonal |
| Concentration | 1 mg/ml |
| Conjugation | Unconjugated |
| Description | Anti-HLA-G Purified Azide Free |
| Supplier | Nordic Biosite |
| Entrez Gene ID | 3135 |
| Format | Purified Azide Free |
| Immunogen | Recombinant human HLA-G refolded with beta2-microglobulin and peptide. |
| Isotype | IgG1 |
| Keywords | MHC (Major Histocompatibility Complex) and Related Antigens (Human) |
| Notes | Human leukocyte antigen G (HLA-G), belonging to MHC class I glycoproteins, plays important roles in both physiological and pathological immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and some other immune cells. It also induces regulatory T cells and anti-inflammatory macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and other. On the other hand, it is expressed in many solid and hematologic malignancies, where it contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an important prognostic factor regarding a poor clinical outcome. Unlike most other MHC glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among other, HLA-G can promote Th2 immunological response and downregulate Th1 immunological response. For its benefits regarding allograft tolerance, including embryo implantation, soluble HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have improved allograft acceptance. On the other hand, increased sHLA-G can also indicate presence of malignant (sometimes also of benign) tumor cells. Another important topic is induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect. Monitoring of HLA-G in patients thus has a wide usage. |
| Previous Article No | AFC-4089-2, AFC-H955NR-0.1 |
| Product Type | Antibodies Primary |
| Protocol | Flow cytometry: Recommended dilution: 1-5 μg/ml; positive control: JEG-3 human choriocarcinoma cell line. Immunocytochemistry: Recommended dilution: 2-5 μg/ml. ELISA: The antibody MEM-G/9 has been tested as the capture antibody in a sandwich ELISA for analysis of human HLA-G in combination with antibody B2M-01 or with antibody W6/32. Coating antibody 10 μg/ml, detection antibody (biotin or peroxidase conjugate) 1 μg/ml. Immunohistochemistry: Recommended dilution: 5-10 μg/ml. |
| Purification | Purified by protein-A affinity chromatography. |
| Purity | > 95% (by SDS-PAGE) |
| Research area | Immunology |
| Size | 0.1 mg |
| Source / Host | mouse |
| Species Reactivity | human |
| Storage | Store at 2-8°C. Do not freeze. |
| Substrate / Buffer | Phosphate buffered saline (PBS), pH 7.4 |
| Technical Specifications | The antibody MEM-G/9 reacts with an extracellular epitope on native form of human HLA-G1 on the cell surface as well as with soluble HLA-G5 isoform in its beta2-microglobulin associated form. Reactivity with HLA-G3 was also reported. The antibody MEM-G/9 is standard reagent thoroughly validated during 3rd International Conference on HLA-G (Paris, 2003). |
| UniProt Number | P17693 |
| Product Page Updated | 2024-01-03T12:18:20.318Z |
